PTC Therapeutics (PTCT) Misses Q2 EPS by 76c

FREE Breaking News Alerts from StreetInsider.com!

E-mail Address

StreetInsider.com Top Tickers, 10/22/2026

1. SPCX
2. NVDA
3. NFLX
4. META
5. TSLA
6. ISRG
7. SMCI
8. RTX
9. GOOGL
10. S

Go back to PTC Therapeutics (PTCT) Misses Q2 EPS by 76c

PTC Therapeutics Provides a Corporate Update and Reports Second Quarter Financial Results

August 4, 2022 4:01 PM EDT

  - Total revenue of $166 million, representing 42% year-over-year growth  

- Upstaza gene therapy granted marketing authorization by European Commission for treatment of AADC deficiency with first commercial patient treated

SOUTH PLAINFIELD, N.J., Aug. 4, 2022 /PRNewswire/ -- PTC Therapeutics, Inc. (NASDAQ: PTCT) today announced a corporate update and financial results for the second quarter ending June 30, 2022. 

"We made significant progress in the second quarter toward achieving our ambitious goals for 2022. We continued to... More